Definitional Guide

What Is a Mammography Medical Outcome Audit?

The MQSA-required audit that tracks the accuracy of mammographic assessments: what it measures, how it works, and what the metrics mean.

Last Reviewed: August 25, 2026

MQSA RequiredAnnual AnalysisPer-Physician TrackingACR Benchmarked

The Audit in Plain Language

A mammography medical outcome auditis a systematic, ongoing tracking process that every MQSA-accredited mammography facility is required to maintain. Its purpose is straightforward: to measure how accurately the facility’s interpreting physicians are assessing mammograms by comparing what they said was there against what biopsy and pathology results showed was actually there.

When a radiologist interprets a mammogram and recommends additional imaging or biopsy, the audit tracks what happened next. Did the patient get the biopsy? Was the finding malignant or benign? How often does this physician’s recommendation for additional workup result in a confirmed cancer diagnosis? Over a population of patients, these outcomes reveal patterns, patterns that are not visible case-by-case but that matter enormously at the program level.

The audit is the mechanism by which a breast imaging program can answer the most important question it faces: Is this program finding breast cancer at the rate it should, without recalling more patients than necessary?

The Core Audit Metrics

MQSA requires calculation and tracking of these performance measures at minimum, per physician and per facility.

Recall Rate / AIR

Abnormal Interpretation Rate: percentage of screening mammograms assessed BI-RADS® 0 (additional imaging needed).

ACR target: 5-12%

Cancer Detection Rate

Number of breast cancers detected per 1,000 mammograms performed.

ACR target: 2-7 per 1,000

PPV1

Positive Predictive Value 1: cancers found per 100 abnormal screening interpretations.

ACR target: 3-8%

PPV2

Positive Predictive Value 2: cancers found per 100 biopsies recommended after diagnostic workup.

ACR target: 20-40%

PPV3 / Biopsy Yield

Positive Predictive Value 3: cancers found per 100 tissue sampling procedures performed.

ACR target: varies by procedure type

Sensitivity & Specificity

Sensitivity: cancers detected as a proportion of all cancers present. Specificity: normal studies correctly called negative.

ACR: sensitivity 75-90%, specificity 88-95%

What a Compliant Audit Program Requires

1

Track every positive assessment

Every mammogram with a BI-RADS® 0, 4, or 5 assessment (and BI-RADS® 3 cases with biopsy recommendation) must be entered into the audit tracking system. This is the input side of the audit: if a positive finding is not captured, it cannot be correlated with its outcome.

2

Monitor follow-up completion

For every positive assessment, the audit must track whether the recommended follow-up (additional imaging or biopsy) occurred. Patients who are lost to follow-up represent both a patient safety concern and an audit data gap. Systematic follow-up monitoring is the operational foundation of a reliable audit.

3

Collect and correlate pathology results

For every biopsy that occurs as a result of a mammographic recommendation, the audit must capture the pathology result, benign or malignant, and link it to the originating mammographic assessment and the interpreting physician who made the recommendation. Incomplete pathology correlation is the most common reason audits fail to support accurate metric calculation.

4

Calculate metrics by physician and by facility

MQSA requires that performance metrics be calculated at both the individual interpreting physician level and the aggregate facility level. Each physician must be able to see how their own recall rate, CDR, and PPV values compare to internal averages and national benchmarks.

5

Analyze annually and compare to benchmarks

Audit data must be formally analyzed at least once per year. The analysis must include comparison to ACR/BCSC benchmarks, identification of physicians whose performance falls outside expected ranges, documentation of findings, and any required corrective action.

6

Document and retain for FDA inspection

All audit records, including tracking data, metric calculations, annual analyses, and any corrective action documentation, must be retained and made available for review during FDA MQSA inspections.

Frequently Asked Questions

A mammography medical outcome audit (sometimes called MMOA or simply a mammography audit) is a structured process that tracks the outcomes of mammographic assessments and correlates them with pathology results and biopsy findings. MQSA requires every accredited mammography facility to maintain a medical audit system. The purpose of the audit is to allow interpreting physicians and facility leadership to evaluate the accuracy of mammographic assessments and identify opportunities to improve screening and diagnostic performance.

Yes. MQSA (the Mammography Quality Standards Act) requires all accredited mammography facilities to maintain a medical audit system. The audit must track all positive mammographic findings, correlate those findings with biopsy results and cancer outcomes, calculate key performance indicators, compare performance against published benchmarks, and analyze results at least annually. The results must be made available for review by the facility's lead interpreting physician and must be reviewable during FDA inspections.

A comprehensive mammography medical outcome audit tracks: all mammograms with a positive assessment (BI-RADS® 0, 4, 5, and 3 with biopsy recommendation); associated biopsy recommendations and procedures; biopsy outcomes and pathology results (benign vs. malignant, histologic type, stage); cancer outcomes for detected lesions; follow-up completion status; and performance metrics including recall rate, cancer detection rate (CDR), positive predictive values (PPV1, PPV2, PPV3), sensitivity, specificity, and biopsy yield. Many facilities also track return rates, TAT (turnaround time), and density distribution.

Under MQSA, audit tracking must support calculation of the following metrics at minimum: recall rate (abnormal interpretation rate / AIR): the percentage of screening mammograms assessed as BI-RADS® 0; cancer detection rate (CDR): cancers detected per 1,000 mammograms performed; positive predictive value 1 (PPV1): cancers per 100 abnormal screening mammograms; positive predictive value 2 (PPV2): cancers per 100 biopsies recommended from imaging; positive predictive value 3 (PPV3): cancers per 100 tissue sampling procedures performed. Sensitivity and specificity are also standard components of a complete audit.

The American College of Radiology (ACR) and the Breast Cancer Surveillance Consortium (BCSC) publish regularly updated performance benchmarks. Current commonly referenced targets include: recall rate (AIR) of 5-12% for screening mammography; cancer detection rate of 2-7 cancers per 1,000 screening mammograms; PPV1 of 3-8%; PPV2 of 20-40%; sensitivity of 75-90%; specificity of 88-95%. Individual physician performance is compared against both national benchmarks and internal facility averages. Values significantly outside these ranges warrant focused review.

MQSA places primary responsibility for the medical audit program on the facility and its lead interpreting physician. The lead interpreting physician is responsible for reviewing individual physician performance data, ensuring annual analysis occurs, and acting on findings that fall outside acceptable performance ranges. In practice, the day-to-day work of tracking findings, collecting pathology results, calculating metrics, and preparing audit reports is often performed by administrative staff, a radiology administrator, or an external audit support service. The interpreting physician remains responsible for reviewing, interpreting, and acting on the results.

MQSA requires that medical audit data be analyzed at least once every 12 months. This analysis must include comparison of each interpreting physician's performance data against established benchmarks and against the facility's internal performance averages. Many facilities conduct more frequent interim reviews, quarterly or semi-annually, to identify trends before they accumulate over a full year. For physicians with low mammography volume (a common issue in facilities that share interpreting physician time across multiple modalities), more frequent monitoring can be important because low case counts can make annual benchmarking statistically unstable.

When an interpreting physician's performance metrics fall outside nationally established benchmark ranges, MQSA requires the facility to take corrective action. The nature of the corrective action depends on the direction and magnitude of the deviation. A recall rate significantly above the upper benchmark may indicate over-calling; a recall rate below the lower benchmark may indicate under-calling. In either case, the facility is expected to document the finding, investigate potential causes, implement a corrective action plan, and follow up to verify improvement. The corrective action process and its documentation must be available for FDA inspection review.

Positive predictive value (PPV) in mammography measures how often a positive assessment actually results in a cancer diagnosis. MQSA tracks three PPV levels: PPV1 measures cancers found among all women recalled from screening (BI-RADS® 0 assessments that led to any imaging recommendation). PPV2 measures cancers found among all women for whom biopsy was recommended after diagnostic workup. PPV3 (also called biopsy yield) measures cancers found among all women who actually underwent tissue sampling. Together, the three PPV values give a layered picture of how efficiently the practice is converting assessments into confirmed diagnoses and how much benign tissue is being sampled relative to malignant.

Recall rate and Abnormal Interpretation Rate (AIR) refer to the same metric, the percentage of screening mammograms with an assessment that triggers a recommendation for additional evaluation (BI-RADS® 0). Some sources use 'recall rate' loosely to describe any return for additional imaging from any cause, including same-day workup. For MQSA audit purposes, the precise term is Abnormal Interpretation Rate (AIR), calculated as the number of BI-RADS® 0 assessments divided by the total number of screening mammograms interpreted. When a facility performs same-day diagnostic workup on screening patients (as some high-volume centers do), AIR calculation requires adjustment to avoid undercounting true screening recall activity.

Cancer detection rate (CDR) is the number of breast cancers detected per 1,000 mammograms performed. It is one of the most direct measures of whether a screening program is succeeding at its primary purpose: finding breast cancer in the people being screened. A CDR significantly below the benchmark range may indicate under-detection, either through assessment practices that are missing findings or through population characteristics such as a low-prevalence screening population. CDR is directly related to recall rate and PPV: an unusually low CDR paired with a high recall rate can suggest a pattern of over-recalling patients without a corresponding improvement in cancer detection, which is one of the most important patterns a mammography audit is designed to surface.

Pathology correlation is the process of connecting mammographic assessments that led to biopsy with the actual biopsy and pathology results. It is the foundation of all PPV calculations and cancer detection metrics. Without complete pathology correlation, audit metrics are mathematically incomplete and unreliable. Incomplete correlation is one of the most common audit problems: it occurs when biopsy procedures happen at a different facility than where the mammogram was interpreted, when pathology results are reported to a different provider, or when the facility lacks a systematic process for retrieving and recording pathology results. A robust audit program has a defined, consistent workflow for retrieving pathology outcomes for every biopsy recommendation the facility generates.

Mammologix supports breast imaging facilities with the full cycle of mammography medical outcome audit operations: tracking positive assessments, monitoring follow-up completion, documenting biopsy recommendations and procedures, collecting and correlating pathology results, calculating MQSA-required performance metrics, generating facility-level and physician-level outcome reports, comparing performance against ACR and BCSC benchmarks, and producing annual audit documentation in a format ready for internal review and FDA inspection. Mammologix has supported mammography audit programs since 1995 and serves facilities ranging from single-location practices to multi-site health system programs.

Medical Outcome Audit Support from Mammologix

Mammologix has supported mammography medical outcome audit programs since 1995. Our audit support includes end-to-end tracking, pathology correlation workflows, metric calculation, physician-level reporting, benchmark comparison, and annual audit documentation: delivered as ready-to-use output, not raw data for your staff to process.

MammoTrackPatient tracking, outcome monitoring, and audit-ready documentation.MammoComplyMQSA compliance support, audit preparation, and inspection readiness.What Is MQSA?The complete guide to the Mammography Quality Standards Act.AIR Score CalculatorCalculate your Abnormal Interpretation Rate vs. ACR benchmarks.
Talk to Mammologix About Audit SupportExplore MammoTrack

About the Author

RL
Richard D. Lippert, Jr.

Founder, President, and Chief Executive Auditor, Mammologix · Breast Imaging Operations since 1995

A registered radiologic technologist, Richard D. Lippert, Jr., Founder, President, and Chief Executive Auditor of Mammologix, has spent more than 30 years in breast imaging operations, from clinical practice and hospital radiology administration to building specialized service platforms for imaging centers nationwide. His work spans mammography tracking, lay communication, FDA/MQSA-related support, medical outcome audit, and the operational systems that help facilities stay compliant and keep patients from falling through the cracks.

View full bio →

Disclaimer

The content, articles, calculators, tools, estimates, projections, derived data, reports, and other materials provided by Mammologix, LLC, powered by I/O Trak, Inc. (“Mammologix”) are provided for informational and educational purposes only.

The information and outputs provided by Mammologix are not intended to serve as, and should not be relied upon as, medical advice, diagnosis, treatment, clinical guidance, financial advice, investment advice, tax advice, legal advice, accounting advice, or any other professional advice.

Information provided by Mammologix may relate to breast health, mammography, imaging, screening, diagnostics, clinical outcomes, healthcare topics, financial calculations, estimates, projections, or other decision-support information. However, such information should not be used to make personal medical, clinical, financial, investment, business, insurance, legal, or other important decisions without consulting an appropriate qualified professional.

Always seek the advice of a licensed physician, radiologist, healthcare provider, financial advisor, accountant, attorney, or other qualified professional with any questions you may have about a medical condition, screening recommendation, imaging result, treatment option, financial matter, or other professional decision. Never disregard professional medical, financial, legal, or other advice, or delay seeking such advice, because of something you have read, calculated, or received through Mammologix.

Any calculators, formulas, estimates, projections, derived medical outcome data, financial calculations, or other tool-generated outputs are provided as estimates only. Results may be affected by user-entered information, assumptions, formula limitations, incomplete or inaccurate data, rounding, software errors, third-party data, changing medical guidelines, changing financial conditions, changes in law or regulation, or other factors. Mammologix does not represent, warrant, or guarantee that any calculation, output, article, estimate, projection, or derived data is accurate, complete, current, reliable, suitable, or appropriate for any particular purpose.

For medical or health-related content and calculators, Mammologix does not provide medical advice, diagnosis, treatment recommendations, diagnostic interpretation, or patient-specific clinical decision-making. Mammologix content and tools are not a substitute for an in-person evaluation, professional medical consultation, diagnostic interpretation, or individualized care from a licensed healthcare provider. In the event of a medical emergency, contact emergency services or a qualified healthcare provider immediately.

For financial, business, tax, investment, or accounting-related calculators or content, Mammologix does not provide financial, investment, tax, legal, accounting, or business advice. Any outputs are estimates only, and actual results may vary materially based on personal circumstances, market conditions, taxes, fees, interest rates, inflation, risk tolerance, regulatory changes, and other factors.

Use of Mammologix content, articles, calculators, tools, and outputs is at your own risk. You are solely responsible for reviewing, verifying, and interpreting any information or results provided and for obtaining appropriate professional advice before relying on or acting upon such information.

Mammologix assumes no liability for any injury, loss, claim, damage, or expense arising from or related to the use of, reliance on, or inability to use any Mammologix content, article, calculator, tool, estimate, projection, derived data, report, or website material. To the fullest extent permitted by law, Mammologix, its owners, officers, employees, contractors, affiliates, licensors, service providers, and agents disclaim all liability for any direct, indirect, incidental, consequential, special, exemplary, punitive, financial, medical, clinical, business, or other damages arising out of or relating to the use of Mammologix materials or outputs.

The information provided by Mammologix does not establish a doctor-patient, provider-patient, radiologist-patient, financial advisor-client, attorney-client, accountant-client, fiduciary, or other professional relationship.

AI Content Disclosure

Some Mammologix content, calculations, summaries, tools, or outputs may be created, edited, generated, or assisted by artificial intelligence tools or automated systems. While Mammologix may review content for accuracy and relevance, AI-assisted or automated materials may contain errors, omissions, inaccuracies, outdated information, or outputs that are incomplete or inappropriate for a particular user, patient, circumstance, or purpose.

Users should independently verify all AI-assisted content, calculator outputs, and automated results with appropriate qualified professionals before relying on them.

Didn't find what you were looking for?

Our team has supported breast imaging centers since 1995. If it's not here, we probably know the answer.

Ask a Question →